Research Paper Volume 12, Issue 14 pp 14897—14917

Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson’s disease models through activating the MEF2-PGC1α and BDNF/CREB pathways

Figure 3. T-006 stimulates MEF2D/PGC1α/Nrf2 signal pathway through regulation of the Akt/GSK3β pathway in PD animal models. (A) Representative Western blots and densitometric analysis the expression of CDK5, p-MEF2D, MEF2D and PGC1α. (B, E) Representative Western blots and densitometric analysis of the expression of p-Akt and p-GSK3β. (C, F) Representative Western blots and densitometric analysis of the expression of Nrf2, HO-1 and TFAM. (D) Representative Western blots and densitometric analysis the expression of MEF2D and PGC1α. Data are expressed as mean±SEM (n=3 per group). #P<0.05, ##P<0.01, ###P<0.001 vs. sham group, and *P<0.05, **P<0.01 and ***P<0.001vs. MPTP or 6-OHDA group.